title: [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
abstract: Recently lymphocytes from patients with cancer have proved to be activated by interleukin 2 (IL-2), and show a strong cytotoxicity. On the basis of this fact, we have tried to inject lymphokine activated killer (LAK) cells and recombinant IL-2 (rIL-2) directly into the cavity of brain tumor. We describe here preliminary results of the local administration of LAK cells and the rIL-2 to patients with malignant gliomas. Lymphocytes from the patients were separated from venous blood on a Ficoll gradient. By culture with rIL-2 for five days, the lymphocytes were activated to generate LAK activity, which was measured by chromium release assay. These LAK cells were capable of killing various kinds of tumor cells including their own cells. For example, their LAK activity to Daudi cell and self tumor cells was approximately 66 and 49%, respectively. These LAK cells showed a strong killing activity in excess of 40 to 70% against various tumor cells. Furthermore, activated killer cells, such as LAK cells, phytohemagglutinin-activated killer cells, and their precursor cells were serologically studied for the recognition of their biological characteristics. The phenotype of these LAK cells were sensitive to Leu 1, 3a, 7, and extremely so to 11 monoclonal antibodies, whereas LAK precursors were mainly sensitive to Leu 11 monoclonal antibodies. This observation led us to think that LAK cells belonged to the polyclonal cell populations. Following the fundamental studies, we applied this adoptive immunotherapy to 12 patients with malignant gliomas in whom standard therapy turned to be unsuccessful. All patients had histological evidence and progressive disease in spite of standard radiochemotherapy and other treatments.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Neurosurgery, Niigata University, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Yoshida
authors.forename: N
authors.initials: N
authors.lastname: Takai
authors.forename: K
authors.initials: K
authors.lastname: Ono
authors.forename: T
authors.initials: T
authors.lastname: Saito
authors.forename: R
authors.initials: R
authors.lastname: Tanaka
mesh_terms: D000293:Adolescent; D000328:Adult; D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy*; D002648:Child; D005260:Female; D005910:Glioma / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive; D007376:Interleukin-2 / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000637:transplantation*; D008297:Male; D008875:Middle Aged
chemical_list: D007376:Interleukin-2